Neurogene Announces Oversubscribed $200 Million Private Placement
Neurogene Inc. (NGNE)
Company Research
Source: Business Wire
Financing included participation from top-tier healthcare fundsProceeds expected to fund Company into the second half of 2027Company to host webcast to review interim clinical data from Phase 1/2 trial of NGN-401 gene therapy for Rett syndrome on November 11 at 4:30 p.m. ET NEW YORK--(BUSINESS WIRE)--Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that it has entered into a securities purchase agreement for a private investment in public equity (“PIPE”) financing that is expected to result in gross proceeds of approximately $200 million to Neurogene, before placement agent fees and offering expenses. The oversubscribed PIPE financing included participation from a U.S.-based healthcare focused investor, RTW Investments, Casdin Capital, EcoR1 Capital, Redmile Group, Great Point Partners, LLC, Commodore Capital and Samsara BioCapital.Pursuant to the
Show less
Read more
Impact Snapshot
Event Time:
NGNE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NGNE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NGNE alerts
High impacting Neurogene Inc. news events
Weekly update
A roundup of the hottest topics
NGNE
News
- Neurogene Inc. (NASDAQ: NGNE) had its price target raised by analysts at Stifel Nicolaus from $44.00 to $60.00. They now have a "buy" rating on the stock.MarketBeat
- Neurogene Inc. (NASDAQ: NGNE) had its price target lowered by analysts at BMO Capital Markets from $65.00 to $60.00. They now have an "outperform" rating on the stock.MarketBeat
- Neurogene Inc. (NASDAQ: NGNE) had its price target raised by analysts at Leerink Partners from $45.00 to $72.00. They now have an "outperform" rating on the stock.MarketBeat
- Neurogene Inc. (NASDAQ: NGNE) had its price target raised by analysts at HC Wainwright from $49.00 to $55.00. They now have a "buy" rating on the stock.MarketBeat
- Neurogene Inc. (NASDAQ: NGNE) had its price target raised by analysts at Robert W. Baird from $54.00 to $72.00. They now have an "outperform" rating on the stock.MarketBeat
NGNE
Earnings
- 8/9/24 - Miss
NGNE
Sec Filings
- 11/12/24 - Form SC
- 11/12/24 - Form 8-K
- 11/8/24 - Form SC
- NGNE's page on the SEC website